1-20 of 28
Philippe Cassier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT222: Efficacy and safety of ceralasertib in the PLANETTE study in patients (pts) with ATM-altered advanced solid tumors (ASTs) or metastatic castration-resistant prostate cancer (mCRPC)

Rahul Aggarwal, Antoine Italiano, Susan Domchek, Oscar Goodman, Sophie Postel-Vinay, Jesus Garcia-Donas, Tanya Dorff, Zachery Reichert, Philippe Cassier, Neal Shore, Catherine Marshall, Graeme Parr, Itziar Irurzun-Arana, Neel Shah, Natalia Lukashchuk, Olga Murina, Daniel Slade, Bienvenu Loembé, Emma Dean, Elhan Sanai, Wassim Abida
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT222.
https://doi.org/10.1158/1538-7445.AM2024-CT222
Published: 05 April 2024
View article titled, Abstract CT222: Efficacy and safety of ceralasertib in the PLANETTE study in patients (pts) with ATM-altered advanced solid tumors (ASTs) or metastatic castration-resistant prostate cancer (mCRPC)
Journal Articles

Abstract CT054: Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study

Byoung Chul Cho, Jonathan Goldman, Natasha Leighl, Filippo De Braud, Ki Hyeong Lee, François Ghiringhelli, Pilar Garrido, Julio Peguero, Benjamin Besse, Philippe Cassier, Nicolas Girard, Maria de Miguel, Rosa Alvarez, Alastair Greystroke, Yuichiro Ohe, Te-Chun Hsia, Joshua C. Curtin, Sanjib Chowdhury, Xuesong Lyu, Grace Gao, Siyang Qu, Patricia Lorenzini, Aastha Kapoor, Priya Kim, Mahadi Baig, Meena Thayu, Roland E. Knoblauch, Sandrine Hiret, Pascale Tomasini
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT054.
https://doi.org/10.1158/1538-7445.AM2024-CT054
Published: 05 April 2024
View article titled, Abstract CT054: Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study
Journal Articles

Abstract CT033: Avelumab combined with regorafenib in solid tumors with tertiary lymphoid structures: A phase 2 REGOMUNE trial cohort

Antoine Italiano, Sophie Cousin, Carine Bellera, Jean-Philippe Guegan, Jean-Philippe Metges, Antoine Adenis, Rastilav Bahleda, Philippe Cassier, Coralie Cantarel, Michele Kind, Jean Palussiere, Lucile Vanhersecke, Alban Bessede
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT033.
https://doi.org/10.1158/1538-7445.AM2024-CT033
Published: 05 April 2024
View article titled, Abstract CT033: Avelumab combined with regorafenib in solid tumors with tertiary lymphoid structures: A phase 2 REGOMUNE trial cohort
Journal Articles

Abstract CT088: EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, is pursuing dose escalation stage of phase I first-in-human study

Carlos Gomez-Roca, Philippe Cassier, Michael Fitzgerald, Lise Davenne, Cristina Costantin, Philippe Rochaix, Jean-Pierre Delord, John Friend, Andrea Nizzardo, Alessia Tagliavini, Marco Pergher, Pierre Fons, Marie Mandron
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT088.
https://doi.org/10.1158/1538-7445.AM2024-CT088
Published: 05 April 2024
View article titled, Abstract CT088: EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, is pursuing dose escalation stage of phase I first-in-human study
Journal Articles

Abstract CT181: First-in-human phase I of anti-VISTA monoclonal antibody W0180 with and without anti-PD-1 pembrolizumab in patients with locally advanced or metastatic solid tumors

Carlos Gomez-Roca, Stéphane Champiat, Philippe Cassier, David Jegou, Marie Primard, Aurélie Pétain, Geneviève Gueguen-Dorbes, Claire Fabre, Ignacio Melero, Aurélien Marabelle
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT181.
https://doi.org/10.1158/1538-7445.AM2024-CT181
Published: 05 April 2024
View article titled, Abstract CT181: First-in-human phase I of anti-VISTA monoclonal antibody W0180 with and without anti-PD-1 pembrolizumab in patients with locally advanced or metastatic solid tumors
Journal Articles

Abstract 1059: Biomarkers analysis on samples from patients in EVT801 clinical trial: Patient characterization and immunomonitoring

Lise Davenne, Michael Fitzgerald, Pierre-Benoit Ancey, Oona Delpuech, Céline Poussereau-Pomié, Michael Esquerre, Michael R. Paillasse, Marie Mandron, Philippe Rochaix, Maha Ayyoub, Clara Maria Scarlata, Christine Caux, Christophe Caux, Philippe Cassier, Carlos Gomez-Roca, Jean-Pierre Delord, John Friend, Pierre Fons
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1059.
https://doi.org/10.1158/1538-7445.AM2024-1059
Published: 22 March 2024
View article titled, Abstract 1059: Biomarkers analysis on samples from patients in EVT801 clinical trial: Patient characterization and immunomonitoring
Journal Articles

Abstract CT032: Trials in progress: a global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma

Alexander Spira, Valentina Gambardella, Shumei Kato, Cesar Batista Perez, Meredith Mckean, Maria Gonzalez Cao, Richard Kim, Chris T Chen, Antoine Italiano, Philippe Cassier, Janice Mehnert, Bartosz Chmielowski, Gerri Lee, Paul Severson, Caro Unger, Xiaowei Guan, Richard Williams, Georgina Long
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT032.
https://doi.org/10.1158/1538-7445.AM2023-CT032
Published: 14 April 2023
View article titled, Abstract CT032: Trials in progress: a global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma
Journal Articles

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

Yonina R. Murciano-Goroff, Rebecca S. Heist, Yasutoshi Kuboki, Takafumi Koyama, Natraj Reddy Ammakkanavar, Antoine Hollebecque, Amita Patnaik, Toshio Shimizu, Alexander I. Spira, Misako Nagasaka, Ji-Youn Han, Wade Thomas Iams, Dustin Deming, Justin Call, Philippe Cassier, Sae-Won Han, Quincy Siu-chung Chu, Rasha Cosman, Gregory Durm, Timothy Burns, Melinda D. Willard, Shiyao Liu, Sophie Callies, Arjun V. Balar, Joshua K. Sabari
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT028.
https://doi.org/10.1158/1538-7445.AM2023-CT028
Published: 14 April 2023
View article titled, Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
Journal Articles

Abstract CT045: A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers

Christophe Le Tourneau, Frédéric Rolland, Amaury Daste, Philippe Cassier, Sébastien Salas, Luis Manso Sánchez, Gerardo Colon-Otero, Lauriane Eberst, Olivier Lantz, Ana Lalanne, Annette Tavernaro, Hakim Makhloufi, Kaïdre Bendjama, Maud Brandely, Jean-Pierre Delord
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT045.
https://doi.org/10.1158/1538-7445.AM2023-CT045
Published: 14 April 2023
View article titled, Abstract CT045: A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers
Journal Articles

Abstract CT190: Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer

Adel Samson, Cristina Smolenschi, Philippe Cassier, Jai V. Patel, Chris Hammond, Marta Kurzawa, Sophie Sainte-Croix, Emma West, Alain Sadoun, Kaidre Bendjama
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT190.
https://doi.org/10.1158/1538-7445.AM2023-CT190
Published: 14 April 2023
View article titled, Abstract CT190: Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer
Journal Articles

Abstract 1015: VEGFR-3 expression profiling by histology to classify patient population for the selective VEGFR-3 inhbitor EVT801

michael Paillasse, pierre-benoit Ancey, Gaelle Badet, Anne Gomez-Brouchet, Janik Selves, philippe Rochaix, Maxime Battistella, Celeste Lebbe, philippe Cassier, carlos Gomez-Roca, Jean-Pierre Delord, Mark Whittaker, Lise Davenne, John Friend, Michael Fitzgerald, James Garner, Pierre Fons
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1015.
https://doi.org/10.1158/1538-7445.AM2023-1015
Published: 04 April 2023
View article titled, Abstract 1015: VEGFR-3 expression profiling by histology to classify patient population for the selective VEGFR-3 inhbitor EVT801
Journal Articles

Abstract A018: Mitazalimab (CD40 agonist) in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Safety data and recommended dose for phase 2 (RP2D) from OPTIMIZE-1, a phase 1b/2 study

Jean-Luc Van Laethem, Ivan Borbath, Hans Prenen, Aurélien Lambert, Karen Geboes, Jean-Frédéric Blanc, Yago Pico de Coaña, Karin Enell-Smith, Lena Schultz, Karin Nordbladh, Peter Ellmark, Sumeet Ambarkhane, Malin Carlsson, Philippe Cassier
Journal: Cancer Research
Cancer Res (2022) 82 (22_Supplement): A018.
https://doi.org/10.1158/1538-7445.PANCA22-A018
Published: 15 November 2022
View article titled, Abstract A018: Mitazalimab (CD40 agonist) in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Safety data and recommended dose for phase 2 (RP2D) from OPTIMIZE-1, a phase 1b/2 study
Journal Articles

Abstract CT040: SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: Interim safety and efficacy results from the AURELIO-03 dose escalation trial

Stephane Champiat, Aurelien Marabelle, Vladimir Galvao, Patricia LoRusso, Peter Grell, Philippe Cassier, Carlos Gomez-Roca, Iphigenie Korakis, Aung Naing, Lenka Palova Jelinkova, Irena Adkins, Ulrich Moebius, Richard Sachse, Sascha Tillmanns, David Bechard, Joachim Kiemle-Kallee, Elena Garralda
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT040.
https://doi.org/10.1158/1538-7445.AM2022-CT040
Published: 15 June 2022
View article titled, Abstract CT040: SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: Interim safety and efficacy results from the AURELIO-03 dose escalation trial
Journal Articles

Abstract CT206: EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, started enrollment for its phase I first-in-human study

Carlos Gomez roca, Philippe Cassier, Marie Mandron, Myriam Estrabaut, Nathalie Delesque-Touchard, Adam C. Smith, Amy Klawitter, Leesa Gentry, Pierre Fons, Michael R. Paillasse, Lise Davenne, Michael Fitzgerald, James Garner, Jean-Pierre Delord
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT206.
https://doi.org/10.1158/1538-7445.AM2022-CT206
Published: 15 June 2022
View article titled, Abstract CT206: EVT801, a novel selective VEGFR-3 inhibitor targeting tumor angiogenesis, started enrollment for its phase I first-in-human study
Journal Articles

Abstract 3203: Cutting edge biomarkers strategy to provide early insights into activity of EVT-801, a novel selective VEGFR-3 inhibitor that targets tumor angiogenesis during the FIH clinical trial

Michael R. Paillasse, James Garner, Michael Fitzgerald, Lise Davenne, Pierre-Benoit Ancey, celine Poussereau-Pomie, Michael Esquerre, Gaelle Badet, Joel Tuyaret, Marie Mandron, Philippe Rochaix, Maha Ayyoub, Clara Maria Scarlata, Christine Ménétrier-Caux, Chrsitophe CAUX, Philippe Cassier, Jean-Pierre Delord, Carlos Gomez Roca, Pierre Fons
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3203.
https://doi.org/10.1158/1538-7445.AM2022-3203
Published: 15 June 2022
View article titled, Abstract 3203: Cutting edge biomarkers strategy to provide early insights into activity of EVT-801, a novel selective VEGFR-3 inhibitor that targets tumor angiogenesis during the FIH clinical trial
Journal Articles

Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements

Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Chigusa Morizane, Juan W. Valle, Thomas B. Karasic, Thomas A. Abrams, Robin Kate Kelley, Philippe Cassier, Junji Furuse, Heinz-Josef Klümpen, Heung-Moon Chang, Li-Tzong Chen, Yoshito Komatsu, Kunihiro Masuda, Daniel Ahn, Yaohua He, Nital Soni, Karim A. Benhadji, John A. Bridgewater
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT010.
https://doi.org/10.1158/1538-7445.AM2021-CT010
Published: 01 July 2021
View article titled, Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
Journal Articles

Abstract LB179: Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas

Kaidre Bendjama, Philippe Cassier, Victor Moreno, Bernard Doger, Emiliano Calvo, Maria de Miguel, Christiane Jungels, Philippe Erbs, Damien Carpentier, Alain Sadoun
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): LB179.
https://doi.org/10.1158/1538-7445.AM2021-LB179
Published: 01 July 2021
View article titled, Abstract LB179: Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas
Journal Articles

Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

Johanna C. Bendell, Philippe Bedard, Yung-Jue Bang, Patricia LoRusso, Stephen Hodi, Michael Gordon, Sandra D'Angelo, Sandra D'Angelo, Jayesh Desai, Elena Garralda, Antoine Italiano, Myung-Ju Ahn, Andres Cervantes, Zev Wainberg, Emiliano Calvo, Marta Gil-Martin, Maria Martinez-Garcia, Rastilav Bahleda, Philippe Cassier, Jean-Pierre Delord, Amy Prawira, Ignacio Melero, Leisha Emens, Emanuela Romano, Karen Miller, Robert W. Hsieh, Cloris Xue, Kari Morrissey, Patrick Twomey, Kelly Gash, Namrata S. Patil, Jane Grogan, Raymond Meng, Byoung Cho, Tae Won Kim
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT302.
https://doi.org/10.1158/1538-7445.AM2020-CT302
Published: 15 August 2020
View article titled, Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors
Journal Articles

Abstract CT150: Optimizing the therapeutic index of HDM2 inhibition: Results from a dose- and regimen-finding Phase I study of NVP-HDM201 in pts with TP53 wt advanced tumors

David M. Hyman, Manik Chatterjee, Filip de Vos, Chia-Chi Lin, Cristina Suárez, David Tai, Philippe Cassier, Noboru Yamamoto, Vincent A. de Weger, Sébastien Jeay, Christophe Meille, Ensar Halilovic, Luisa Mariconti, Matthieu Klopfenstein, Nelson Guerreiro, Rajkumar Radhakrishnan, Emil T. Kuriakose, Sebastian Bauer
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT150.
https://doi.org/10.1158/1538-7445.AM2017-CT150
Published: 01 July 2017
View article titled, Abstract CT150: Optimizing the therapeutic index of HDM2 inhibition: Results from a dose- and regimen-finding Phase I study of NVP-HDM201 in pts with <em>TP53</em> wt advanced tumors
Journal Articles

Abstract CT154: Optimization of the dose and schedule of an HDM2 inhibitor NVP-HDM201 in a first-in-human Phase I study using a mechanism-based PK/PD model

Christophe Meille, Nelson Guerreiro, Astrid Jullion, Sebastian Bauer, Manik Chatterjee, Filip de Vos, Chia-Chi Lin, Cristina Suárez Rodríguez, David Tai, Philippe Cassier, Noboru Yamamoto, Vincent A. de Weger, Matthieu Klopfenstein, Luisa Mariconti, Emil T. Kuriakose, David M. Hyman
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT154.
https://doi.org/10.1158/1538-7445.AM2017-CT154
Published: 01 July 2017
View article titled, Abstract CT154: Optimization of the dose and schedule of an HDM2 inhibitor NVP-HDM201 in a first-in-human Phase I study using a mechanism-based PK/PD model